Regeneron (REGN) faces a 3% stock drop after losing an appeals case over its Eylea drug patents against Amgen (AMGN).

EDT Regeneron (REGN) down 3% after appeals court decision in Amgen (AMGN) patent fightLight Up your Portfolio with Spark:Easily identify ...

Regeneron Pharmaceuticals (REGN) appealed a decision of the United States District Court for the Northern District of West Virginia denying ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

Eylea has been a significant revenue driver for Regeneron, and any potential impact on its sales due to competition from biosimilars is closely watched by investors. The court’s ruling thus represents ...

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...

The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab ...

The RNA inhibitor reduces levels of oxidized phospholipids, which are presumed to promote atherosclerosis, by more than 93%.